Compare Mesoblast Limited (MESO) vs Sea Limited (SE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Sea Limited — how do they compare? Mesoblast Limited trades at $14.24 (market cap $1.75B), while Sea Limited trades at $95.7 (market cap $56.89B). The key difference: Sea Limited is far larger — about 32.5× Mesoblast Limited's market cap, and Mesoblast Limited is more actively traded (239,027 versus 5,359,457). Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 15 Days and Sea Limited for 102 Days on average.
| MESO | SE | |
|---|---|---|
Market Cap | $1.75B | $56.89B |
Volume | 239,027 | 5,359,457 |
Sector | Health | Consumer Cyclical |
52-Week High | $20.96 | $188.00 |
52-Week Low | $13.19 | $78.16 |
Typical Hold Time | 15 Days | 102 Days |
Enterprise Value | $1.83B | $51.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Sea Limited (SE) trades at $95.25, down 0.62% with a bearish technical signal. The company shows strong fundamental improvement with revenue growing from $12.4B in 2022 to $22.9B in 2025, achieving profitability with net income of $1.58B. Analyst consensus remains strongly bullish with 70% buy ratings and a $153.67 price target, though recent insider selling and technical weakness create near-term headwinds. Operating cash flow has turned positive at $5.02B, supporting the company's growth trajectory.
Sea Limited presents a compelling growth story with improving profitability and strong analyst support, though technical weakness and insider selling warrant caution. The stock trades at a discount to analyst targets with solid fundamentals, but investors should monitor execution risks in competitive e-commerce and digital entertainment markets. The current price level near support at $91-92 offers potential entry for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Sea Limited
Sea Limited offers information technology services. The Company provides online personal computer and mobile digital content, e-commerce, and payment platforms. Sea serves customers worldwide.
Read more on SE →
